login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
BIOMARIN PHARMACEUTICAL INC (BMRN) Stock News
NASDAQ:BMRN -
US09061G1013
-
Common Stock
58.58
USD
+0.51 (+0.88%)
Last: 8/22/2025, 8:00:02 PM
58.58
USD
0 (0%)
After Hours:
8/22/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BMRN Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: Chartmill
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential
19 days ago - By: Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Exceeds Q2 2025 Earnings Expectations, Shares Climb After Hours
5 days ago - By: The Motley Fool
- Mentions:
TSLA
META
MSFT
SBUX
...
Predicting the Next Rule Breaker Buyout
6 days ago - By: Zacks Investment Research
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
11 days ago - By: Zacks Investment Research
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
11 days ago - By: Benzinga
Is BioMarin Pharmaceutical Gaining or Losing Market Support?
12 days ago - By: Zacks Investment Research
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
12 days ago - By: Yahoo Finance
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105
19 days ago - By: Zacks Investment Research
- Mentions:
SNY
GMAB
IMCR
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
19 days ago - By: The Motley Fool
BioMarin (BMRN) Q2 Revenue Jumps 16%
19 days ago - By: Zacks Investment Research
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
19 days ago - By: Zacks Investment Research
- Mentions:
MRUS
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
19 days ago - By: BioMarin Pharmaceutical Inc.
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
23 days ago - By: Benzinga
What's Next: Biomarin Pharmaceutical's Earnings Preview
23 days ago - By: BioMarin Pharmaceutical Inc.
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
26 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
a month ago - By: Zacks Investment Research
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
a month ago - By: Yahoo Finance
- Mentions:
MS
ASND
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside
2 months ago - By: Yahoo Finance
- Mentions:
UBS
AAPL
MRK
Merck Strikes $10 Billion Deal to Buy Verona Pharma
Please enable JavaScript to continue using this application.